Entrada Therapeutics (TRDA) Competitors $5.80 -0.08 (-1.36%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$5.80 0.00 (-0.09%) As of 08/1/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TRDA vs. LENZ, ORIC, AVXL, REPL, MLYS, PROK, IMNM, GHRS, NRIX, and QUREShould you be buying Entrada Therapeutics stock or one of its competitors? The main competitors of Entrada Therapeutics include LENZ Therapeutics (LENZ), Oric Pharmaceuticals (ORIC), Anavex Life Sciences (AVXL), Replimune Group (REPL), Mineralys Therapeutics (MLYS), ProKidney (PROK), Immunome (IMNM), GH Research (GHRS), Nurix Therapeutics (NRIX), and uniQure (QURE). These companies are all part of the "pharmaceutical products" industry. Entrada Therapeutics vs. Its Competitors LENZ Therapeutics Oric Pharmaceuticals Anavex Life Sciences Replimune Group Mineralys Therapeutics ProKidney Immunome GH Research Nurix Therapeutics uniQure Entrada Therapeutics (NASDAQ:TRDA) and LENZ Therapeutics (NASDAQ:LENZ) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, earnings, analyst recommendations, institutional ownership, dividends, risk, valuation and profitability. Do institutionals and insiders have more ownership in TRDA or LENZ? 86.4% of Entrada Therapeutics shares are owned by institutional investors. Comparatively, 54.3% of LENZ Therapeutics shares are owned by institutional investors. 8.1% of Entrada Therapeutics shares are owned by insiders. Comparatively, 6.9% of LENZ Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Which has more risk & volatility, TRDA or LENZ? Entrada Therapeutics has a beta of -0.11, suggesting that its stock price is 111% less volatile than the S&P 500. Comparatively, LENZ Therapeutics has a beta of 0.42, suggesting that its stock price is 58% less volatile than the S&P 500. Is TRDA or LENZ more profitable? Entrada Therapeutics has a net margin of 14.39% compared to LENZ Therapeutics' net margin of 0.00%. Entrada Therapeutics' return on equity of 5.84% beat LENZ Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Entrada Therapeutics14.39% 5.84% 4.61% LENZ Therapeutics N/A -25.63%-24.43% Does the media prefer TRDA or LENZ? In the previous week, LENZ Therapeutics had 29 more articles in the media than Entrada Therapeutics. MarketBeat recorded 29 mentions for LENZ Therapeutics and 0 mentions for Entrada Therapeutics. Entrada Therapeutics' average media sentiment score of 1.00 beat LENZ Therapeutics' score of 0.61 indicating that Entrada Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Entrada Therapeutics Positive LENZ Therapeutics Positive Which has preferable valuation and earnings, TRDA or LENZ? Entrada Therapeutics has higher revenue and earnings than LENZ Therapeutics. LENZ Therapeutics is trading at a lower price-to-earnings ratio than Entrada Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEntrada Therapeutics$172.22M1.28$65.63M$0.817.16LENZ TherapeuticsN/AN/A-$49.77M-$1.90-15.77 Do analysts prefer TRDA or LENZ? Entrada Therapeutics presently has a consensus target price of $25.67, indicating a potential upside of 342.53%. LENZ Therapeutics has a consensus target price of $49.60, indicating a potential upside of 65.55%. Given Entrada Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Entrada Therapeutics is more favorable than LENZ Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Entrada Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25LENZ Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17 SummaryEntrada Therapeutics beats LENZ Therapeutics on 12 of the 15 factors compared between the two stocks. Get Entrada Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TRDA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TRDA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TRDA vs. The Competition Export to ExcelMetricEntrada TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$223.16M$3.00B$5.48B$9.51BDividend YieldN/A2.43%4.73%4.08%P/E Ratio7.1617.6228.6723.80Price / Sales1.28179.18373.9066.65Price / Cash3.7141.9535.4557.96Price / Book0.518.508.275.55Net Income$65.63M-$55.06M$3.24B$259.03M7 Day Performance-11.31%-3.98%-3.69%-4.59%1 Month Performance-20.22%9.59%4.33%4.46%1 Year Performance-60.68%6.72%25.95%18.03% Entrada Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TRDAEntrada Therapeutics3.2087 of 5 stars$5.80-1.4%$25.67+342.5%-63.7%$223.16M$172.22M7.16110Positive NewsHigh Trading VolumeLENZLENZ Therapeutics1.5155 of 5 stars$33.58-0.4%$46.60+38.8%+21.7%$949.37MN/A-18.97110Trending NewsEarnings ReportAnalyst ForecastAnalyst RevisionORICOric Pharmaceuticals4.5629 of 5 stars$11.06+0.5%$18.57+67.9%-4.6%$938.32MN/A-5.9180News CoveragePositive NewsAVXLAnavex Life Sciences3.6596 of 5 stars$11.16+1.6%$44.00+294.3%+70.2%$937.88MN/A-20.2940News CoverageUpcoming EarningsREPLReplimune Group3.8863 of 5 stars$12.32+1.9%$21.00+70.5%-25.6%$931.98MN/A-4.01210Trending NewsAnalyst UpgradeOptions VolumeGap DownHigh Trading VolumeMLYSMineralys Therapeutics2.558 of 5 stars$13.62-4.3%$32.25+136.8%+13.4%$927.44MN/A-3.6528News CoverageInsider TradePROKProKidney3.2738 of 5 stars$3.22+2.2%$6.25+94.1%+29.4%$922M$80K-5.373Upcoming EarningsGap DownIMNMImmunome2.0688 of 5 stars$10.82+2.3%$23.33+115.7%-29.7%$920.59M$9.04M-3.4040News CoveragePositive NewsGap DownGHRSGH Research2.2794 of 5 stars$19.50+11.0%$32.00+64.1%+11.4%$914.13MN/A-24.6810NRIXNurix Therapeutics2.5151 of 5 stars$11.25+0.4%$29.31+160.6%-48.6%$857M$54.55M-4.31300News CoverageAnalyst ForecastQUREuniQure2.4186 of 5 stars$14.50-3.3%$37.82+160.8%+83.0%$821.09M$27.12M-3.30500Trending NewsEarnings ReportUpcoming EarningsAnalyst ForecastAnalyst Revision Related Companies and Tools Related Companies LENZ Therapeutics Alternatives Oric Pharmaceuticals Alternatives Anavex Life Sciences Alternatives Replimune Group Alternatives Mineralys Therapeutics Alternatives ProKidney Alternatives Immunome Alternatives GH Research Alternatives Nurix Therapeutics Alternatives uniQure Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TRDA) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredA new rule goes live in July — and the banks are quietly crushing itA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Entrada Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Entrada Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free TRDA Stock Alerts